Inhibikase Therapeutics
IKT
IKT
11 hedge funds and large institutions have $301K invested in Inhibikase Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Holders
11
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$10.5K | |
| 2 | +$4.72K | |
| 3 | +$3K | |
| 4 |
Morgan Stanley
New York
|
+$2.12K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
+$1.13K |
Top Sellers
| 1 | -$259K | |
| 2 | -$23.2K | |
| 3 | -$6.86K | |
| 4 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$1.69K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$207 |